Class of diabetes drug linked to increased risk of irritable bowel disease

Class of diabetes drug linked to increased risk of irritable bowel disease

March 29 2018 A study has shown that dipeptidylpeptidase-4 inhibitors may increase the risk of...

Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

March 29 2018 Mefloquine is safe to use for malaria prevention during pregnancy, a Cochrane...

Anti-epilepsy drugs exposure in womb associated with poor school performance years later

Anti-epilepsy drugs exposure in womb associated with poor school performance years later

March 27 2018 Exposure to anti-epilepsy drugs in the womb has been linked to significantly poorer...

COPD flare-ups may only need 5 days of systemic steroids

COPD flare-ups may only need 5 days of systemic steroids

March 26 2018 A new study has suggested that shorter doses of systemic corticosteroids may be as...

Numbers of people with heart condition living with multiple other diseases increases

Numbers of people with heart condition living with multiple other diseases increases

March 12 2018 Almost a quarter of people (24.3%) with heart disease are also living with five or...

  • Class of diabetes drug linked to increased risk of irritable bowel disease

    Class of diabetes drug linked to increased risk of irritable bowel disease

    Thursday, 29 March 2018 11:27
  • Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

    Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

    Thursday, 29 March 2018 11:21
  • Anti-epilepsy drugs exposure in womb associated with poor school performance years later

    Anti-epilepsy drugs exposure in womb associated with poor school performance years later

    Tuesday, 27 March 2018 09:36
  • COPD flare-ups may only need 5 days of systemic steroids

    COPD flare-ups may only need 5 days of systemic steroids

    Monday, 26 March 2018 12:34
  • Numbers of people with heart condition living with multiple other diseases increases

    Numbers of people with heart condition living with multiple other diseases increases

    Monday, 12 March 2018 16:31

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a woman coughing image cbAugust 31 2017

Oral corticosteroids do not reduce the symptom duration or severity of acute lower respiratory tract infections in adults who do not have asthma, a study has concluded.

 Researchers studied outcomes in 398 non-asthmatic adults who were given prednisolone 40mg once daily for five days. Median cough duration was five days in both the prednisolone and placebo groups. Mean symptom severity was 1.99 points in the prednisolone group and 2.16 points in the placebo group.

In addition, “no significant treatment effects were observed for duration or severity of other acute lower respiratory tract infection symptoms, duration of abnormal peak flow, antibiotic use, or non-serious adverse events.”

The UK study was funded by NIHR School for Primary Care Research and published in JAMA.

Alastair Hay, a GP and Professor of Primary Care in the Bristol Medical School at the University of Bristol and lead author, said: “Chest infections are one of the most common problems in primary care and often treated inappropriately with antibiotics. Corticosteroids, like prednisolone, are increasingly being used to try to reduce the symptoms of chest infections, but without sufficient evidence.

“Our study does not support the continued use of steroids as they do not have a clinically useful effect on symptom duration or severity. We would not recommend their use for this group of patients.”

Links:
NIHR announcement      
NIHR SPCR announcement            
AD Hay et al. ‘Effect of Oral Prednisolone on Symptom Duration and Severity in Non-asthmatic Adults With Acute Lower Respiratory Tract Infection’. JAMA. 2017;318(8):721-730.  

Clinical News

April 20 2018 Doctors have not been prevented from prescribing over-the counter medicines, but should use proper clinical judgement, a health minister has said.
April 20 2018 Doctors have not been prevented from prescribing over-the counter medicines, but should use proper clinical judgement, a health minister has said. A question was raised following last...